Online inquiry

IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15268MR)

This product GTTS-WQ15268MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets phosphatidylserine. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15268MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5047MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ5948MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ14187MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ4939MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5026MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ9463MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ4213MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW